See the DrugPatentWatch profile for Enbrel
When does Enbrel’s patent or exclusivity expire?
“Enbrel” (etanercept) was first approved in the U.S. in 1998, so today’s issue for many buyers and patients is less about a single “expiration date” and more about when specific patents and market exclusivities end for the product and its formulations. Those dates can differ by indication, strength, and jurisdiction, and they can also change as litigation or regulatory events shift the relevant exclusivity windows.
For the most up-to-date, search-friendly timelines tied to specific Enbrel patents and exclusivity (including likely expiry/marketing-expiration dates tracked by the industry), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/ (search for “Enbrel” there).
What do people usually mean by “Enbrel expiration date”?
Searchers often mean one of these:
- The end of patent protection for Enbrel in the U.S. (or another country), after which additional manufacturers may be able to market competing products.
- The end of regulatory exclusivity periods (which can block approval even if a patent is no longer in force).
- A specific date for a given biosimilar’s launch window (since Enbrel is a biologic and competition often comes through biosimilars).
Has Enbrel already lost its exclusivity in the U.S.?
Enbrel’s original biologic exclusivity and earlier patents are long past due to the product’s 1990s origin, but individual later-introduced patents (for manufacturing, delivery, method-of-use, or formulation changes) may have extended protection for certain claims. That’s why the exact “expiration” you hear about can vary depending on which patent family or exclusivity you are looking at.
Where can I check the exact date for my situation (country, strength, biosimilar)?
The “right” date depends on:
- Country (U.S. vs. EU vs. other markets)
- Product version (e.g., different presentations/strengths)
- Whether you care about patent expiry, exclusivity expiry, or biosimilar launch timing
- Whether you’re tracking the originator (Enbrel) or a specific biosimilar competitor
DrugPatentWatch.com tracks these kinds of dates and links them to patent families and regulatory status, which makes it easier to get a precise, date-specific answer for the market you care about.
Sources
- [1] https://www.drugpatentwatch.com/